INVO Fertility, Inc (NASDAQ:IVF) Stock Short Interest Falls 74.1%

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 50,118 shares, a drop of 74.1% from the September 15th total of 193,695 shares. Based on an average daily volume of 151,104 shares, the short-interest ratio is presently 0.3 days. Currently, 2.0% of the company’s shares are short sold.

INVO Fertility Trading Down 10.5%

INVO Fertility stock traded down $0.08 during midday trading on Tuesday, reaching $0.65. 179,958 shares of the stock traded hands, compared to its average volume of 1,913,292. The firm has a market cap of $1.63 million, a PE ratio of -0.02 and a beta of 2.39. The company has a current ratio of 0.71, a quick ratio of 0.67 and a debt-to-equity ratio of 0.03. The company has a 50-day simple moving average of $0.99 and a two-hundred day simple moving average of $1.44. INVO Fertility has a 12-month low of $0.63 and a 12-month high of $84.40.

INVO Fertility (NASDAQ:IVF) last released its earnings results on Friday, August 14th. The company reported $0.35 earnings per share (EPS) for the quarter. The company had revenue of $2.18 million for the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of INVO Fertility in a research note on Monday, August 3rd. Wall Street Zen raised INVO Fertility to a “hold” rating in a research note on Saturday, August 29th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, INVO Fertility presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

INVO Fertility Company Profile

INVO Fertility, Inc (NASDAQ: IVF) is a fertility-care company focused on expanding access to in vitro fertilization (IVF) through its INVO Procedure and related medical technology. The company develops, manufactures and commercializes INVOcell, an FDA-cleared medical device designed to provide a controlled environment for fertilizing and incubating embryos inside a woman’s body, as an alternative to conventional laboratory-based embryo culture.

The INVO Procedure uses INVOcell as part of an assisted-reproductive treatment process that can be offered by fertility specialists and clinics.